VEGFR2

VEGFR2 (Vascular Endothelial Growth Factor Receptor 2), also known as KDR or Kinase insert domain receptor, is a transmembrane receptor tyrosine kinase expressed predominantly on endothelial cells. It is the principal transducer of VEGF-A signaling and the dominant driver of new blood vessel formation in both physiological and pathological contexts.

Why it matters in peptide research

VEGFR2 activation initiates a cascade of intracellular events — including PI3K/Akt, MAPK/ERK, and eNOS pathways — that together promote endothelial cell proliferation, migration, and tube formation. Without adequate VEGFR2 signaling, tissues struggling to recover from injury cannot establish the vascular supply needed to deliver oxygen and nutrients to regenerating cells.

In the context of peptide research, VEGFR2 has attracted considerable attention because certain peptides appear capable of upregulating its expression or enhancing its downstream signaling without the systemic toxicity associated with small-molecule VEGFR agonists. This makes receptor modulation via peptides a potentially cleaner lever for promoting controlled angiogenesis in wound healing, muscle repair, and tendon remodeling.

BPC-157 is the most studied peptide in this regard. Preclinical data suggest BPC-157 upregulates VEGFR2 expression in vascular endothelium, which may explain its observed acceleration of wound closure and tendon-to-bone healing in animal models. The receptor upregulation appears to sensitize tissue to circulating VEGF, amplifying the angiogenic signal without requiring supraphysiological VEGF concentrations.

Peptides that act on this

BPC-157 — preclinical evidence for VEGFR2 upregulation; associated with accelerated tissue repair and angiogenesis in tendon, gut, and muscle injury models.
TB-500 (Thymosin Beta-4) — promotes VEGF expression upstream, indirectly increasing ligand availability for VEGFR2 signaling.

The signalling cascade in detail

VEGF-A dimer binds two VEGFR2 monomers, inducing receptor dimerisation.
Trans-autophosphorylation of cytoplasmic tyrosine residues — particularly Y1175 and Y1214 — creates docking sites for downstream effectors.
PLCγ pathway (via Y1175) — activates PKC and the MAPK/ERK cascade, driving proliferation.
PI3K/Akt pathway — promotes endothelial cell survival and vascular permeability.
eNOS activation — generates nitric oxide, mediating vasodilation and vessel-tone modulation.
TSAd / Src pathway (via Y951) — drives cell migration and lamellipodium formation.
Receptor internalisation and lysosomal degradation provide negative-feedback termination.

Therapeutic relevance — both directions

VEGFR2 has been the most pharmacologically targeted pro- and anti- angiogenic receptor in modern medicine. Anti-angiogenic agents — bevacizumab (VEGF-A binder), ranibizumab, aflibercept, the multi-kinase inhibitors sunitinib and pazopanib (which inhibit VEGFR2 kinase activity directly) — are licensed for solid tumours, age-related macular degeneration, and proliferative diabetic retinopathy. The clinical case for anti-angiogenic VEGFR2 modulation is well-established.

Pro-angiogenic VEGFR2 modulation — the rationale claimed for tissue- repair peptides — has not produced an approved medicine despite decades of work. This asymmetry is informative: it suggests that promoting angiogenesis pharmacologically is clinically harder than it sounds.

Peptides and stacks that invoke this receptor

BPC-157 — preclinical evidence for VEGFR2 upregulation; associated with accelerated tissue repair and angiogenesis in tendon, gut, and muscle injury models.
TB-500 — promotes VEGF expression upstream, indirectly increasing ligand availability for VEGFR2 signalling, and drives endothelial cell migration through actin-cytoskeletal effects.
GHK-Cu — modulates angiogenic and matrix-remodelling signalling.
The BPC-157 + TB-500 combination evidence review and the BPC-157 + TB-500 + GHK-Cu tissue-repair review both lean on VEGFR2-axis claims.
See also the angiogenesis / VEGFR2 mechanism map.

Common misconceptions

VEGFR2 activation is sometimes conflated with unrestricted tumour- promoting angiogenesis. In reality, physiological VEGFR2 signalling is tightly regulated by receptor internalisation and negative feedback; the angiogenesis driven by peptide-mediated VEGFR2 upregulation in injury models is context-dependent and self-limiting once tissue repair is complete in those models.

Nonetheless, the theoretical tumour-promotion concern is not absent. Active or recently-treated cancer is a recognised contraindication for pro-angiogenic peptide research contexts. See: contraindication deep-dive.